Clinical Trial Update: Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a full-spectrum medicinal cannabis extract with 0.08% THC (NTI164) for Pediatric Acute-onset Neuropsychiatric Syndrome (PA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute-onset Neuropsychiatric Syndrome

Drugs mentioned

• NTI164

Snippet

Sponsor: Fenix Innovation Group | Conditions: PANS Pediatric Acute-Onset Neuropsychiatric Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING